DMRA
Damora Therapeutics, Inc.
Next earnings Aug 3, 2026 · consensus $-0.43 EPS
Last earnings -11.1% on 2026-03-10
$25.36
▲ +12.36%$25.36▲ +652.52%
over 1Y
L $2.58EODHDH $34.14
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+12.4%
1W+6.2%
1M+0.6%
3M-0.5%
YTD+16.2%
1Y+652.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.08x).
The read
Middling fundamentals offset by an attractive price (~20% below fair value) — worth a look on the value angle.
Damora Therapeutics, Inc. shows limited reported revenue, and -87.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$52.2M | -$61.2M | -$39.9M | -$22.3M | -$211M |
| Net income | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$210M |
| Diluted EPS | -$2.05 | -$2.43 | -$36.08 | -$18.53 | $3.98 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.27B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-13.7%
FCF yield-0.5%
Quality & risk
ROIC (est.)-69.3%
Free cash flow-$6.92M
Total debt—
Net cash$258M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+4460.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗144Filing2026-06-22open ↗8-KPeriod ending 2026-04-282026-06-17open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-12open ↗3Period ending 2026-05-012026-05-08open ↗8-KPeriod ending 2026-04-282026-05-04open ↗ARSPeriod ending 2025-12-312026-05-01open ↗DEF 14APeriod ending 2026-04-292026-04-29open ↗DEFA14AFiling2026-04-29open ↗SCHEDULE 13G/AFiling2026-04-23open ↗
Frequently asked
- Is Damora Therapeutics, Inc. (DMRA) a buy?
- DMRA currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.08x).
- What is DMRA's fair value?
- A Modified-Graham model based on DMRA's SEC fundamentals estimates a fair value of about $30.45. It is an estimate from reported earnings, not a price target.
- Is DMRA overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, DMRA currently appears undervalued relative to its SEC-grounded earnings power.
- What is Damora Therapeutics, Inc.'s quality score?
- DMRA scores 50.01960784313725/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001800315, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 6:52:55 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.